Articles

Takeda said Tuesday its trial of darvadstrocel in the treatment of complex Crohn's Perianal Fistulas didn't meet its primary endpoint based on topline data.

Drug previously rejected by regulators gets green light and is set to launch later this year

Impact Biomedical has filed for an initial public offering, according to a filing with the Securities and Exchange Commission.

Forecast for data-center server growth exceeds any that occurred during the rise of the internet, so while long-term is positive, risk of overbuilding is high.

Companies are beefing up spending on their own AI capabilities, all while AI revenues largely have yet to materialize

‘You can imagine how the ability to do business while sitting on your dock increases housing demand.’

United guided for lower profits at the end of the year, depending on how long flights to Tel Aviv will be suspended.

Shares of J.B. Hunt Transport Services Inc. fell after hours on Tuesday after the company reported third-quarter results that missed Wall Street's expectations.

President Biden's planned trip to Israel Wednesday soothes market jitters, with investors locked on oil price moves.

After halting on Monday, trading in Rite Aid's stock resumed Tuesday.

U.S. Bancorp no longer has to meet Category II banking requirements after its December acquisition of MUFG Union Bank.

As investors snap up long-dated Treasurys following a historic rout that has seen the price of some issues cut in half, some traders are using esoteric "bond math" to justify making big contrarian bets.